CSL (OTCMKTS:CSLLY) Shares Gap Down – Here’s Why

CSL Limited Sponsored ADR (OTCMKTS:CSLLY) gapped down prior to trading on Thursday . The stock had previously closed at $25.13, but opened at $23.70. CSL shares last traded at $24.88, with a volume of 60,032 shares trading hands.

Analysts Set New Price Targets

Several brokerages have commented on CSLLY. Royal Bank Of Canada downgraded shares of CSL from a “moderate buy” rating to a “hold” rating in a research report on Wednesday, February 11th. Zacks Research upgraded shares of CSL from a “strong sell” rating to a “hold” rating in a research report on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy”.

CSL Stock Performance

The business’s 50 day simple moving average is $39.01 and its two-hundred day simple moving average is $53.70.

CSL Company Profile

CSL Limited (OTCMKTS: CSLLY) is a global biotechnology company headquartered in Melbourne, Australia that develops, manufactures and delivers a range of plasma-derived and recombinant therapeutics, vaccines and related services. Its principal businesses include CSL Behring, which focuses on specialty biotherapies for bleeding disorders, immune deficiencies, hereditary angioedema and other serious conditions; Seqirus, an influenza vaccine company formed following CSL’s acquisition of Novartis’ influenza vaccine business; and CSL Plasma, a network of plasma collection centers that supplies the raw material for many of its therapies.

The company’s product portfolio spans immunoglobulins, clotting factor concentrates, albumin and other protein-based treatments used in the management of chronic and acute rare diseases, as well as seasonal and pandemic influenza vaccines.